Paradigm Capital Management Inc. NY Sells 20,700 Shares of Mednax, Inc (MD)

Paradigm Capital Management Inc. NY decreased its holdings in shares of Mednax, Inc (NYSE:MD) by 26.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 57,575 shares of the company’s stock after selling 20,700 shares during the period. Paradigm Capital Management Inc. NY owned 0.06% of Mednax worth $2,483,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in MD. Nomura Asset Management Co. Ltd. increased its stake in shares of Mednax by 1.3% during the first quarter. Nomura Asset Management Co. Ltd. now owns 11,300 shares of the company’s stock valued at $784,000 after purchasing an additional 140 shares in the last quarter. Xact Kapitalforvaltning AB increased its stake in shares of Mednax by 3.8% during the second quarter. Xact Kapitalforvaltning AB now owns 18,106 shares of the company’s stock valued at $1,093,000 after purchasing an additional 664 shares in the last quarter. NN Investment Partners Holdings N.V. increased its stake in shares of Mednax by 8.0% during the second quarter. NN Investment Partners Holdings N.V. now owns 30,490 shares of the company’s stock valued at $1,840,000 after purchasing an additional 2,265 shares in the last quarter. State of Alaska Department of Revenue increased its stake in shares of Mednax by 6.2% during the second quarter. State of Alaska Department of Revenue now owns 4,393 shares of the company’s stock valued at $265,000 after purchasing an additional 257 shares in the last quarter. Finally, Mn Services Vermogensbeheer B.V. increased its stake in shares of Mednax by 527.2% during the second quarter. Mn Services Vermogensbeheer B.V. now owns 15,228 shares of the company’s stock valued at $919,000 after purchasing an additional 12,800 shares in the last quarter. 96.44% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Paradigm Capital Management Inc. NY Sells 20,700 Shares of Mednax, Inc (MD)” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://ledgergazette.com/2017/11/22/paradigm-capital-management-inc-ny-trims-stake-in-mednax-inc-md.html.

A number of research firms have recently commented on MD. Citigroup Inc. cut their price target on shares of Mednax from $52.00 to $47.00 and set a “neutral” rating on the stock in a report on Friday, November 3rd. Robert W. Baird increased their price target on shares of Mednax from $47.00 to $48.00 and gave the company a “neutral” rating in a report on Friday, November 3rd. Jefferies Group LLC reiterated a “hold” rating and set a $44.00 price target on shares of Mednax in a report on Friday, November 3rd. KeyCorp set a $51.00 price target on shares of Mednax and gave the company a “buy” rating in a report on Wednesday, November 1st. Finally, BMO Capital Markets began coverage on shares of Mednax in a report on Monday, October 16th. They set a “market perform” rating and a $46.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $54.50.

Shares of Mednax, Inc (MD) traded down $0.07 during mid-day trading on Wednesday, reaching $48.42. 1,452,500 shares of the company traded hands, compared to its average volume of 1,054,054. Mednax, Inc has a 52 week low of $40.56 and a 52 week high of $72.13. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $4,541.34, a PE ratio of 14.83, a P/E/G ratio of 1.56 and a beta of 0.32.

Mednax (NYSE:MD) last released its quarterly earnings results on Wednesday, November 1st. The company reported $0.87 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.87. Mednax had a net margin of 7.76% and a return on equity of 10.80%. The business had revenue of $868.95 million for the quarter, compared to the consensus estimate of $864.78 million. During the same period last year, the firm earned $1.09 earnings per share. The company’s quarterly revenue was up 4.9% on a year-over-year basis. analysts predict that Mednax, Inc will post 3.1 EPS for the current year.

In other news, Director Cesar L. Alvarez sold 10,668 shares of the firm’s stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $42.59, for a total transaction of $454,350.12. Following the sale, the director now directly owns 44,215 shares in the company, valued at approximately $1,883,116.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider John C. Pepia sold 3,000 shares of the firm’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $42.85, for a total transaction of $128,550.00. Following the sale, the insider now owns 35,569 shares in the company, valued at $1,524,131.65. The disclosure for this sale can be found here. 2.40% of the stock is currently owned by company insiders.

About Mednax

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Institutional Ownership by Quarter for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply